The 11th Seoul Symposium on Bone Health
& the 35th Spring Scientific Congress of the Korean Society for Bone and Mineral Research

Adi Cohen

Associate Professor of Medicine at CUIMC
Director, Early Onset Osteoporosis Center
Metabolic Bone Diseases Program
Division of Endocrinology, Department of Medicine
Columbia University, College of Physicians & Surgeons, New York, NY

Curriculum Vitae



Educational Background & Professional Experience

2015-Present	Associate Professor of Medicine at CUIMC, Columbia University
2005-2015	Assistant Professor of Clinical Medicine, Columbia University
2003-2005	Master's Degree Program, Duke Clinical Research Training Program
	Fellowship in Women's Health, Duke University and Durham VA Med Cntr
2000-2003	Fellowship in Endocrinology, Diabetes and Metabolism, Columbia University
1997-2000	Internship and Residency, Internal Medicine, New York University
1993-1997	New York University School of Medicine
1989-1993	Haverford College

Research Interests

Dr. Cohen's current research focuses on the use of imaging tools for the noninvasive assessment of bone microstructure, bone biopsy techniques for the study of bone structure and bone metabolism, and genetic studies to better understand disease mechanisms and etiologies. Current studies investigate the pathogenesis of both idiopathic osteoporosis in premenopausal women (IOP) and pregnancy and lactation associated osteoporosis (PLO), as well as various treatment options for women with these conditions.

Publications

- 1. Cohen A, Kamanda-Kosseh M, Dempster DW, Zhou H, Müller R, Goff E, Colon I, Bucovsky M, Stubby J, Nickolas TL, Stein EM, Recker RR, Lappe JM, Shane E. Women with pregnancy and lactation associated osteoporosis (PLO) have low bone remodeling rates at the tissue level. J Bone Miner Res. 2019 Sep;34(9): 1552–1561. PMCID: PMC6744311.
- 2. Cohen A, Hostyk J, Baugh EH, Buchovecky CM, Aggarwal VS, Recker RR, Lappe JM, Dempster DW, Zhou H, Kamanda-Kosseh M, Bucovsky M, Stubby J, Goldstein DB, Shane E. Whole exome sequencing reveals potentially pathogenic variants in a small subset of premenopausal women with idiopathic osteoporosis. Bone 2022 Jan; 154:116253. PMCID: PMC8671293.
- 3. Cohen A, Shiau S, Nair N, Recker RR, Lappe JM, Dempster DW, Nickolas TL, Zhou H, Agarwal S, Kamanda-Kosseh M, Bucovsky M, Williams JM, McMahon DJ, Stubby J, Shane E. Effect of teriparatide on bone remodeling and density in premenopausal idiopathic osteoporosis: a phase II trial. J Clin Endocrinol Metab 2020 Oct 1; 105(10): e3540-e3556. PMCID: PMC8921657.
- 4. Shane E, Shiau S, Recker RR, Lappe JM, Agarwal S, Kamanda-Kosseh M, Bucovsky M, Stubby J, Cohen A. Denosumab after teriparatide in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 2022 Mar; 107(4):e1528-e154. PMID 34849989.
- 5. Agarwal S, Shane E, Lang T, Shiau S, Kamanda-Kosseh M, Bucovsky M, Lappe JM, Stubby J, Recker RR, Hu Y, Wang Z, Guo XE, Cohen A. Spine volumetric BMD and strength in premenopausal idiopathic osteoporosis: Effect of teriparatide followed by denosumab. J Clin Endocrinol Metab 2022 Jun; 107(7):e2690-e2701. PMCID: PMC9391607.